

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		10/590,672	
				Filing Date		October 23, 2007	
				First Named Inventor		Kung	
				Group Art Unit		1642	
				Examiner Name		Lei Yao	
				Attorney Docket Number		20363-025 NATL	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	4,987,071	01/22/91	Cech et al.	435	91	
	*A2	5,116,742	05/26/92	Cech et al.	435	91	
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
/L Y/	B1	WO	95/20960	ARCH DEVELOPMENT CORPORATION	08/10/95		
/L Y/	B2	WO	98/06391	MOR-RESEARCH APPLICATIONS LTD	02/19/98		
	B3	WO	99/32619	THE CARNEGIE INSTITUTE OF WASHINGTON	07/01/99		
	B4	WO	00/44895	KREUTZER	08/03/00		X
	B5	WO	01/29058 A1	UNIVERSITY OF MASSACHUSETTS	04/26/01		
	B6	WO	01/75164 A2	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	10/11/01		
	B7	WO	01/87307 A2	CELGENE CORP.	11/22/01		
	B8	WO	01/89304 A1	UNIVERSITY OF ROCHESTER	11/29/01		
	B9	WO	01/92513 A1	JOHNSON & JOHNSON RESEARCH PTY LIMITED	12/06/01		
	B10	WO	02/092599 A1	NOVARTIS AG	11/21/02		
	B11	WO	02/102804 A1	KAROLINSKA INNOVATIONS AB	12/27/02		
	B12	WO	02/16620 A2	UNIVERSITY OF SHEFFIELD	02/28/02		
	B13	WO	02/17904 A1	GOVERNMENT OF MALAYSIA	03/07/02		
	B14	WO	02/080987 A1	PROGENICS PHARMACEUTICALS, INC.	10/17/02		
	B15	WO	02/29858 A2	INFINEON TECHNOLOGIES NORTH AMERICA CORP.	04/11/02		
	B16	WO	03/027246 A2	NOVO NORDISK A/S	04/03/03		
	B17	WO	2004/030627 A2	BRISTOL-MYERS SQUIBB COMPANY	04/15/04		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
L.Y.	C1	Anderson et al., "Role of Cytokines in Multiple Myeloma", <i>Semin. Hematol.</i> , 36(1, Suppl. 3):14-20 (1999)
	C2	Bartel et al., "Isolation of New Ribozymes from a Large Pool of Random Sequences", <i>Science</i> , 261:1411-1418 (1993)
	C3	Beech et al., "Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol", <i>Oncol. Rep.</i> , 8(2):325-329 (2001)
	C4	Benini et al., "Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells", <i>Clin. Cancer Res.</i> , Abstract only, 7(6):1790-1797 (2001)
	C5	Blum et al., "Substrate Competitive Inhibitors of IGF-1 Receptor Kinase", <i>Biochem.</i> , 39:15705-15712 (2000)
	C6	Database CA Online, Chemical Abstracts Service, Columbus, Ohio, US: May 22, 2002, Wen et al., "Tyrophostin AG 1024 modulates radiosensitivity in human breast cancer cells", XP002977524, retrieved from STN Database accession No. 2002:141503, Abstract & <i>Brit. J. Cancer</i> , 85(12):2017-2021 (2001)
	C7	Fukuda et al., "Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells", <i>J. Biol. Chem.</i> , 277(41):38205-38211 (2002)
	C8	GenBank Accession No. AF064078, August 10, 2000
	C9	GenBank Accession No. AH002704, November 8, 1994
	C10	GenBank Accession No. AY260957, April 3, 2003
	C11	GenBank Accession No. AY790940, November 2, 2004
	C12	GenBank Accession No. CR541861, October 16, 2008
	C13	GenBank Accession No. EO2872, November 4, 2005
	C14	GenBank Accession No. M22373, November 8, 1994
	C15	GenBank Accession No. NM000875, April 10, 2009
	C16	GenBank Accession No. NM00876, April 19, 2009
	C17	GenBank Accession No. NM004215, January 25, 2009
	C18	GenBank Accession No. S62621, August 25, 1993
	C19	GenBank Accession No. T27620, September 6, 1995
	C20	GenBank Accession No. T29467, September 6, 1995
	C21	GenBank Accession No. X05113, April 4, 1997
	C22	GenBank Accession No. L15440, January 6, 1995
	C23	GenBank Accession No. M22372, November 8, 1994
	C24	Hailek et al., "Multiple myeloma: Increasing evidence for a multistep transformation process", <i>Blood</i> , 91:3-21 (1998)
	C25	Haselhoff et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities", <i>Nature</i> , 334(6183):585-591 (1988)
	C26	Helene et al., "Control of Gene Expression by Triple Helix-Forming Oligonucleotides. The Antigene Strategy", <i>Ann. N.Y. Acad. Sci.</i> , 660:27-36 (1992)
	C27	Helene, C., "The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides", <i>Anti-cancer Drug Des.</i> , 6(6):569-584 (1991)
	C28	Lei et al., "Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells", <i>Anticancer Res.</i> , 19(1A):221-228 (1999)
	C29	Maher, III, J.L., "DNA Triple-Helix Formation: An Approach to Artificial Gene Repressors?" <i>Bioassays</i> , 14(12):807-815 (1992)
	C30	Mitsiades et al., "Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications", <i>Blood</i> , 99(12):4525-4530 (2002)
V	C31	Mitsiades et al., "Biologic sequelae of nuclear factor- κ B blockade in multiple myeloma: therapeutic applications", 99(11):4079-4086 (2002)

Date of Deposit: May 26, 2009

Attorney Docket No.: 20363-025 NATL

/L.Y./	C32	Mitsiades et al., "Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors", <i>Cancer Cell</i> , 5:221-230 (2004)
↓	C33	Mitsiades et al., "Molecular sequelae of proteasome inhibition in human multiple myeloma cells" <i>Proc. Natl. Sci. USA</i> , 99(22):14374-14379 (2002)
↓	C34	Mitsiades et al., "Proteomic Analyses in Waldenstrom's Macroglobulinemia and Other Plasma Cell Dyscrasias", <i>Semin. Oncol.</i> , 30(2):156-160 (2003)
↓	C35	Mitsiades et al., "The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications", <i>Blood</i> , 101(6):2377-2380 (2003)
↓	C36	Nakashima et al., "Serum Interleukin 6 as a Prognostic Factor in Patients with Prostate Cancer", <i>Clin. Cancer Res.</i> , 6:2702-2706 (2000)
↓		

* By the waiver of 37 CFR 1.98(a)(2)(ii) copies of the U.S. Patents A1-A2 are not submitted.

Examiner	/Lei Yao/	Date Considered	05/27/2009
----------	-----------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.